Vibalogics, a global contract development and manufacturing organization (CDMO), has initiated Phase I of its planned $150 million investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, MA.   The three-year investment plan includes the build out of a 110,000 sq. ft facility totaling $150 million across redevelopment, equipment and personnel.   The CDMO which specializes in the production of oncolytic viruses, viral vector vaccines and viral vector gene...